A randomized Phase 3 U-ENDURE maintenance study compared the safety and efficacy of upadacitinib with placebo for the treatment of patients with moderate-to-severe Crohn disease.
The researchers discussed the use of risankizumab induction therapy and its ability to treat symptoms that greatly affect the lives of patients with Crohn disease. The research was presented at ACG 2022.
...
According to a recent study, subcutaneous maintenance dosing of risankizumab at 52 weeks is effective and well-tolerated in patients with moderate-to-severe Crohn disease who had a delayed response to...
Authors of a new study measured differences in patient radiation exposure and the scatter effect among endoscopy personnel between the use of conventional and artificial intelligence-enabled fluoroscopy...
Because the treatment options for eosinophilic gastrointestinal disorders are limited, authors of the ENIGMA study evaluated whether the AK002 antibody could be a therapy option in eosinophilic gastritis...
Lindsay Sobotka, DO, from the Ohio State University Wexner Medical Center, presented her research at the ACG 2019 Annual Meeting about the risk of complications during pregnancy and outcomes among pregnant...
The authors of a new study presented at the ACG 2019 Annual Meeting examined the association between statin use and risk of HCC among more than 20,000 patients with HCC.
The authors of a new study presented at the ACG 2019 Annual Meeting evaluated data of more than 200 adult gastroenterology patients to characterize patients with avoidant/restrictive food intake disorder.
...
The researchers of a new phase 3 clinical trial presented at the ACG 2019 Annual Meeting sought to determine the safety and efficacy of budesonide oral suspension in adolescents and adults with EoE.
